Trials / Approved For Marketing
Approved For MarketingNCT03906331
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Detailed description
N/A for expanded access
Conditions
- Non Small Cell Lung Cancer
- Medullary Thyroid Cancer
- Colon Cancer
- Breast Cancer
- Pancreatic Cancer
- Papillary Thyroid Cancer
- Other Solid Tumors With Evidence of Activating RET Alteration
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selpercatinib | Open-label expanded access |
Timeline
- First posted
- 2019-04-08
- Last updated
- 2025-01-17
Locations
64 sites across 13 countries: United States, Australia, France, Germany, Hong Kong, Israel, Italy, Japan, New Zealand, Poland, Singapore, Spain, Switzerland
Source: ClinicalTrials.gov record NCT03906331. Inclusion in this directory is not an endorsement.